pubmed-article:14588111 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:14588111 | lifeskim:mentions | umls-concept:C0007807 | lld:lifeskim |
pubmed-article:14588111 | lifeskim:mentions | umls-concept:C0876926 | lld:lifeskim |
pubmed-article:14588111 | lifeskim:mentions | umls-concept:C0078939 | lld:lifeskim |
pubmed-article:14588111 | lifeskim:mentions | umls-concept:C0003595 | lld:lifeskim |
pubmed-article:14588111 | lifeskim:mentions | umls-concept:C1515926 | lld:lifeskim |
pubmed-article:14588111 | pubmed:issue | 10 | lld:pubmed |
pubmed-article:14588111 | pubmed:dateCreated | 2003-10-31 | lld:pubmed |
pubmed-article:14588111 | pubmed:abstractText | There is evidence that apolipoprotein E (apoE) and amyloid beta-protein (Abeta), which are implicated in the pathology of chronic neurodegenerative disorders, are involved in the response of the brain to acute injury; however, human in vivo evidence is sparse. We conducted a prospective observational study to determine the magnitude and time-course of alterations in cerebrospinal fluid (CSF) apoE and Abeta concentrations after traumatic brain injury (TBI), and the relationship of these changes to severity of injury and clinical outcome. Enzyme linked immunosorbant assay (ELISA) was used to assay apoE, Abeta(1-40) and Abeta(1-42) in serial CSF samples from 13 patients with TBI and 13 controls. CSF S100B and tau were assayed as surrogate markers of brain injury. There was a significant decrease in CSF apoE (p < 0.001) and Abeta (p< 0.001) after TBI contrasting the observed elevation in CSF S100B (p < 0.001) and tau (p < 0.001) concentration. There was significant correlation (r = 0.67, p = 0.01) between injury severity and the decrease in Abeta(1-40) concentration after TBI. In vivo, changes in apoE and Abeta concentration occur after TBI and may be important in the response of the human brain to injury. | lld:pubmed |
pubmed-article:14588111 | pubmed:language | eng | lld:pubmed |
pubmed-article:14588111 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14588111 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:14588111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14588111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14588111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14588111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14588111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14588111 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:14588111 | pubmed:month | Oct | lld:pubmed |
pubmed-article:14588111 | pubmed:issn | 0897-7151 | lld:pubmed |
pubmed-article:14588111 | pubmed:author | pubmed-author:NicollJames... | lld:pubmed |
pubmed-article:14588111 | pubmed:author | pubmed-author:PetzoldAxelA | lld:pubmed |
pubmed-article:14588111 | pubmed:author | pubmed-author:KeirGeoffG | lld:pubmed |
pubmed-article:14588111 | pubmed:author | pubmed-author:KerrMaryM | lld:pubmed |
pubmed-article:14588111 | pubmed:author | pubmed-author:ThompsonEdE | lld:pubmed |
pubmed-article:14588111 | pubmed:author | pubmed-author:KayAndrew DAD | lld:pubmed |
pubmed-article:14588111 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:14588111 | pubmed:volume | 20 | lld:pubmed |
pubmed-article:14588111 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:14588111 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:14588111 | pubmed:pagination | 943-52 | lld:pubmed |
pubmed-article:14588111 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:meshHeading | pubmed-meshheading:14588111... | lld:pubmed |
pubmed-article:14588111 | pubmed:year | 2003 | lld:pubmed |
pubmed-article:14588111 | pubmed:articleTitle | Alterations in cerebrospinal fluid apolipoprotein E and amyloid beta-protein after traumatic brain injury. | lld:pubmed |
pubmed-article:14588111 | pubmed:affiliation | Department of Neurosurgery, University of Glasgow, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom. adk4z@clinmed.gla.ac.uk | lld:pubmed |
pubmed-article:14588111 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:14588111 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:14588111 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
entrez-gene:348 | entrezgene:pubmed | pubmed-article:14588111 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:14588111 | lld:entrezgene |
lhgdn:association:34830 | lhgdn:found_in | pubmed-article:14588111 | lld:lhgdn |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14588111 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14588111 | lld:pubmed |